f Intravenous Sub-dissociative Dose Ketamine versus Morphine for Acute Traumatic Pain in Geriatric Patients in the Emergency Department: A Case Series

Citation

Motov S, Drapkin J, Likourezos A, Flom P, Fassassi C, et al. (2018) Intravenous Subdissociative- Dose Ketamine versus Morphine for Acute Traumatic Pain in Geriatric Patients in the Emergency Department: A Case Series. Int J Crit Care Emerg Med 4:053. doi.org/10.23937/2474-3674/1510053

Copyright

© 2018 Motov S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CASE SERIES | OPEN ACCESSDOI: 10.23937/2474-3674/1510053

Intravenous Sub-dissociative Dose Ketamine versus Morphine for Acute Traumatic Pain in Geriatric Patients in the Emergency Department: A Case Series

Sergey Motov1, Jefferson Drapkin1*, Antonios Likourezos1, Peter Flom2, Catsim Fassassi3, John Marshall1 and Ronald Simon3

1Department of Emergency Medicine, Maimonides Medical Center, USA

2Peter Flom Consulting, USA

3Department of Trauma Surgery, Maimonides Medical Center, USA

Abstract

Study objective

We compared analgesic efficacy and safety of sub-dissociative dose ketamine (SDK) to morphine for managing acute traumatic pain in geriatric emergency department (ED) patients.

Methods

A subset of geriatric patients from a randomized double-blind trial experiencing moderate to severe acute traumatic pain who received SDK at 0.3 mg/kg or morphine at 0.1 mg/kg by short intravenous infusion over 15 minutes was analyzed at 15, 30, 60, 90, and 120 minutes post-medication administration. Primary outcome was reduction in pain at 30 minutes. Secondary outcomes included adverse effects and rates of rescue analgesia.

Results

Twelve patients (5 in the SDK group and 7 in the morphine group) were eligible for analysis. The change in mean pain scores was not significantly different in SDK and morphine groups: 8.6 versus 9.1 at baseline and 5.8 versus 5.9 at 30 minutes. Patients in SDK group had a greater percentage change in pain reduction from the baseline in comparison to morphine at the 15-minute mark (48.8% decrease versus 30.8% decrease). In the morphine group more, patients experienced dizziness (57% vs. 20%) and fatigue (71% vs. 40%), and required more rescue analgesia at 60, 90 and 120 minutes (14% vs. 0%; 14% vs. 0%, and 29% vs. 0%, respectively).

Conclusion

SDK at 0.3 mg/kg over 15 minutes provided analgesia comparable to morphine for short-term treatment of acute pain with a reduced need for rescue analgesia for up to two hours and minimal rates of rates of psychoperceptual adverse effects.